ENTRY       D03639                      Drug
NAME        Daclizumab (USAN/INN);
            Zenapax (TN);
            Zinbryta (TN)
FORMULA     C6394H9888N1696O2012S44
EXACT_MASS  144031.1268
MOL_WEIGHT  144119.9425
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGSSVKV SCKASGYTFT SYRMHWVRQA PGQGLEWIGY INPSTGYTEY
            NQKFKDKATI TADESTNTAY MELSSLRSED TAVYYCARGG GVFDYWGQGT LVTVSSASTK
            GPSVFPLAPS SKSTSGGTAA LGCLVKDYFP EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS
            LSSVVTVPSS SLGTQTYICN VNHKPSNTKV DKKVEPKSCD KTHTCPPCPA PELLGGPSVF
            LFPPKPKDTL MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTKP REEQYNSTYR
            VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL PPSRDELTKN
            QVSLTCLVKG FYPSDIAVEW ESNGQPENNY KTTPPVLDSD GSFFLYSKLT VDKSRWQQGN
            VFSCSVMHEA LHNHYTQKSL SLSPGK
            (Light chain)
            DIQMTQSPST LSASVGDRVT ITCSASSSIS YMHWYQQKPG KAPKLLIYTT SNLASGVPAR
            FSGSGSGTEF TLTISSLQPD DFATYYCHQR STYPLTFGQG TKVEVKRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: H22-H96, H143-H199, H260-H320, H366-H424, H225-H'225, H228-H'228, L23-L87, L133-L193, H219-L213)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
REMARK      ATC code: L04AC01
EFFICACY    Immunosuppressant, Anti-CD25 antibody
  DISEASE   Multiple sclerosis [DS:H01490]
  TYPE      Monoclonal antibody
TARGET      IL2RA (CD25) [HSA:3559] [KO:K05068]
  PATHWAY   hsa04060(3559)  Cytokine-cytokine receptor interaction
            hsa04144(3559)  Endocytosis
            hsa04630(3559)  JAK-STAT signaling pathway
            hsa04640(3559)  Hematopoietic cell lineage
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AC Interleukin inhibitors
                 L04AC01 Daclizumab
                  D03639  Daclizumab (USAN/INN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D03639  Daclizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL2RA (CD25)
                 D03639  Daclizumab (USAN/INN)
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03639
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03639
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03639
DBLINKS     CAS: 152923-56-3
            PubChem: 17397742
///
